TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World

Natalizumab (Tysabri) Re-Initiation of Dosing

NCT00297232 ·Status: TERMINATED ·Phase: PHASE3

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

NCT01485003 ·Status: COMPLETED

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

NCT03399981 ·Status: COMPLETED

Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

NCT04580381 ·Status: COMPLETED

Ireland Natalizumab (TYSABRI) Observational Program

NCT01943526 ·Status: COMPLETED

A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

NCT00424788 ·Status: COMPLETED ·Phase: EARLY_PHASE1

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

NCT00536120 ·Status: COMPLETED ·Phase: PHASE4

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

NCT04832399 ·Status: COMPLETED

Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS

NCT00884481 ·Status: COMPLETED

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

NCT01658384 ·Status: COMPLETED

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)

NCT01405820 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

NCT06127095 ·Status: COMPLETED

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

NCT01071512 ·Status: COMPLETED ·Phase: NA

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

NCT00937677 ·Status: COMPLETED

Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS

NCT02965170 ·Status: COMPLETED

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

NCT02159573 ·Status: COMPLETED

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

NCT00464074 ·Status: COMPLETED

The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis

NCT01455220 ·Status: COMPLETED ·Phase: NA

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05925049 ·Status: ACTIVE_NOT_RECRUITING

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT05532163 ·Status: TERMINATED ·Phase: PHASE4

Natalizumab Re-Initiation of Dosing

NCT00306592 ·Status: COMPLETED ·Phase: PHASE3

A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years

NCT01847287 ·Status: COMPLETED

JC-Virus (JCV) Antibody Program

NCT01070823 ·Status: COMPLETED

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

NCT01416155 ·Status: COMPLETED ·Phase: PHASE2

Natalizumab Subcutaneous Immunogenicity and Safety Study

NCT02142192 ·Status: TERMINATED ·Phase: PHASE2